Werewolf Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel J. Hicklin
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1030 Massachusetts Avenue Watertown MA United States of America 02138
- IPO Date
- Apr 30, 2021
- CIK
- 0001785530
- Website
- werewolftx.com
- Similar Companies
- Business
- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) is a clinical-stage biopharmaceutical company that develops conditionally activated therapeutics engineered to stimulate the body's immune system for treating cancer and other immune-mediated conditions; its proprietary PREDATOR platform designs INDUKINE molecules that remain inactive in peripheral tissue and activate selectively in the tumor microenvironment to enhance efficacy while minimizing systemic toxicity. The company offers a pipeline of immunomodulatory product candidates, including WTX-124, a systemically delivered, conditionally activated interleukin-2 (IL-2) INDUKINE evaluated in Phase 1/1b trials as monotherapy and in combination with pembrolizumab for solid tumors such as metastatic melanoma, renal cell carcinoma, cutaneous squamous cell carcinoma, and non-small cell lung cancer; WTX-330, a conditionally activated interleukin-12 (IL-12) INDUKINE advancing toward a Phase 1/2 dose- and regimen-finding trial in advanced solid tumors; and preclinical programs such as WTX-712 (IL-21 INDUKINE), WTX-518 (IL-18 INDUKINE) for cancer, WTX-921 (IL-10 INDUKINE) for inflammatory bowel disease and other inflammatory conditions, WTX-1011, and T cell engagers. Founded in 2017 and headquartered in Watertown, Massachusetts, Werewolf Therapeutics focuses on immuno-oncology and related fields, targeting patients with solid tumors and immunotherapy-resistant cancers through clinical trials conducted primarily in the United States. Recent developments include receipt of U.S. FDA Fast Track Designation for WTX-124 in October 2025; presentation of Phase 1 data for WTX-124 and WTX-330 at the Society for Immunotherapy of Cancer's 40th Annual Meeting in November 2025 demonstrating promising anti-tumor activity and tolerability; advancement of WTX-124 expansion arms with interim monotherapy data expected in the first half of 2025 and combination data in the fourth quarter of 2025, alongside plans to engage regulators on potential registrational pathways including accelerated approval; initiation of the WTX-330 Phase 1/2 trial in the first quarter of 2025; and a cash position providing runway through at least the second quarter of 2026, with preclinical portfolio partnership pursuits ongoing. The company maintains a partnered program, JZP898 (formerly WTX-613), and operates without current revenue from product sales as it progresses candidates through development.
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Analysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) PT at $3.75
Luke Evnin Sells 24,678 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Luke Evnin Sells 24,962 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Luke Evnin Sells 18,568 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics Announces Pipeline and Business Updates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics to Participate in the BIO International Convention
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference